Purpose of review Peripheral T-cell lymphomas (PTCLs) represent diverse and aggressive malignancies, with few recent therapeutic improvements. Recent high-throughput genomic studies have revealed the complex mutational landscape of these rare diseases. These novel findings provide the grounds to a more comprehensive classification of these diseases, reflected in the 2017 WHO classification.
INTRODUCTION
Peripheral T-cell lymphomas (PTCLs) represent less than 15% of all non-Hodgkin lymphomas worldwide. Recent high-throughput molecular and genomic profiling studies have generated many discoveries that significantly advanced our understanding of the pathogenesis and pathobiology of these diseases. The genetic alterations in PTCL target multiple pathways. Highly recurrent mutations occur in different classes of epigenetic modifiers [1] [2] [3] 4 & ,5 & ], in T-cell receptor (TCR) and coreceptors signaling pathways [6 & ,7] , and in components or regulators of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. There is established or presumed evidence that the resulting functional deregulations represent pathogenic mechanisms contributing to induce or maintain some attributes of the malignant phenotype [8] . Although a few variants are characteristic of certain entities, for example RHOA G17V , no novel disease-defining mutation has been found, there is major overlap in the mutational landscapes of different entities, and ALK-positive anaplastic largecell lymphoma (ALCL) essentially remains the only PTCL defined by a specific genomic rearrangement. Some of these new molecular findings have been incorporated into the revised edition of the WHO classification (2017) as they refine classification and diagnostic criteria [9] . The currently recognized
ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA AND OTHER NODAL LYMPHOMAS OF T FOLLICULAR HELPER DERIVATION
Apart from the constellation of histological and clinico-biological features characteristic of the disease, angioimmunoblastic T-cell lymphoma (AITL) definition also refers to its T follicular helper (TFH) derivation [11] . The mutational landscape of AITL comprises frequent mutations in three genes directly or indirectly involved in the regulation of DNA methylation/hydroxymethylation. Sensitive sequencing methods detect TET2 DNMT3A and IDH2 mutations in about 80% [12] [13] [14] , 20-30% [12, 15, 16] and 20-30% of the cases [17] , respectively. TET2 is an aketoglutarate-dependent dioxygenase, involved in the successive oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) to 5-formylmethylcytosine and 5-carboxymethylcytosine, resulting in the demethylation of 5-cytosine, through the thymine DNA glycosylase-mediated base excision system [18] . Thus, TET2 plays an important role in active cytosine demethylation. DNMT3A is a de-novo DNA methyltransferase, involved in the transformation of 5-cytosine to 5mC [19] . Mutations in TET2 and DNMT3A are loss-of-function and distributed along the coding sequences of the genes, with few hotspots, such as the dominant-negative DNMT3A R882X mutant [20] . IDH2 mutations occur specifically at the R172 residue [16, 21] , and confer a neoenzymatic activity producing D-2 hydroxyglutarate [22] . This metabolite, physiologically present at very low levels, inhibits numerous a-ketoglutaratedependent dioxygenases, including TET proteins or histone demethylases [23] . Although IDH1/2 and TET2 mutations in acute myeloid leukemia are mutually exclusive, both resulting in a specific methylation profile [24] , for unknown reasons they frequently coexist in AITL. Although TET2, DNMT3A and IDH2 mutations have in principle opposite effect on cytosine methylation levels, they all individually result in decreased 5hmC levels. Interestingly, compared to normal TFH cells, 5hmC levels are decreased in AITL, and more generally in PTCL, regardless of mutations, suggesting that epigenetic deregulation is a general event during the lymphomagenesis [21] . However, the functional consequences of these changes in cytosine methylation/hydroxymethylation are yet poorly understood and warrant further comprehensive studies. A missense mutation encoding the pG17 V substitution in RHOA GTPase is detected in 50 [7] . Initially reported as highly recurrent events [29] , these fusions are in fact detected in less than 10% of patients [7, 30] . ICOS-CD28 fusions are more prevalent and likely result in an enhanced CD28 signal [7] . CTLA4-CD28 fusions are less common and have the unique feature to link extracellular CTLA4 engagement to an activating signal through CD28 intracellular moiety. Anti-CTLA4 antibody ipilimumab can block this signal and clinical efficacy was reported in one case [31] .
An interesting finding in AITL is that TET2 and DNMT3A mutations can be detected not only in
KEY POINTS
Mutational profiling of the many PTCL entities has revealed diverse mutational landscapes which are advancing our understanding of the pathogenesis of these rare and aggressive diseases.
The highly prevalent nodal lymphomas of follicular helper T-cell origin are characterized by a multistep oncogenetic pathway involving epigenetic deregulation related to TET2, DNMT3 or IDH2 mutations, and gainof-function mutations affecting genes related to TCR signaling pathway.
Although PTCLs are usually aggressive disease, several indolent entities are recognized, including CD30 þ ALCL associated with breast implants, and indolent clonal proliferations of mature T cells in the gastrointestinal tract. Formerly not identified as an entity and considered as of peripheral T-cell lymphoma, not otherwise specified Adapted from [9] , with summary of changes and novelties in comparison to the previous edition [10] a Designates provisional entities.
neoplastic T cells, but also in CD34-derived colonies [32] , in CD34 þ cells [17] and in B cells isolated from AITL biopsies [33 & ,34] . Furthermore, variant allele frequencies of TET2 and DNMT3A are higher than those of RHOA or IDH2. This supports that the former two mutations can occur in a hematopoietic progenitor or stem cell. Conversely, RHOA [33 & ] and IDH2 [33 & ,35] mutations are restricted to tumor cells, indicating that they are likely a second hit in an oncogenic multistep process (Fig. 1) . Furthermore, as TET2 or DNMMT3A mutations can be detected at significant levels in the blood of elderly individuals, reflecting at least partly a clonal hematopoiesis [36] [37] [38] [39] , they are not sufficient by themselves to induce a T-cell neoplasm.
Several mouse models further support the hypothesis of a multistep oncogenic process. The combination of TET2 inactivation and DNMT3 mutation can induce various hematological diseases including PTCL, only after transplantation and with a low penetrance [40] , whereas TET2 inactivation and RHOA G17V altogether result in the development of an AITL-like disease with a much higher penetrance. The first model used engineered TET2-deficient T cells, transfected with RHOA G17V construct. Recipient mice developed AITL-like disease, where decrease in FOXO1 appeared essential for tumor cells survival [41 & ]. Two transgenic mouse models with expression of RHOA G17V in the T-cell compartment demonstrated the role of RHOA G17V in T-cell development, TFH differentiation and in inducing autoimmunity. However, additional TET2 inactivation is required for lymphoma development [42 && ,43] . It is expected that these mouse models will facilitate testing of novel therapies. Of note, mouse TFH lymphomas are dependent on ICOS/ PIK3/MTOR signaling [42 && ,43], which may represent innovative therapeutic targets.
Recent epidemiological data indicate that AITL prevalence is much higher than previously reported [44, 45] . Moreover, expression of a TFH immunophenotype was also found in the very rare follicular variant of PTCL (F-PTCL), and about 20-30% of PTCL previously classified as 'not otherwise specified' (TFH-PTCL) [3, 46, 47] . This raised the question whether AITL, F-PTCL and TFH-PTCL represent morphological variants of the same disease or distinct diseases with similar phenotype. A recent study showed that these lymphomas also have comparable clinical presenting features including auto-immunity, and outcome, and similar genomic imbalances and mutational profiles. A same frequency of TET2, DNMT3A and RHOA mutations was found in AITL, F-PTCL and TFH-PTCL [13,48 & ], only IDH2 mutations being more frequently present in AITL [15, 16] . This suggests a common oncogenic process in these lymphomas, which is reflected in the 2017 classification by grouping them as related diseases (Table 1) .
ANAPLASTIC LARGE CELL LYMPHOMAS
Anaplastic large cell lymphomas (ALCLs) include four entities having in common a large-cell anaplastic morphology, strong CD30 expression and frequent phospho-STAT3 activation: anaplastic lymphoma kinase (ALK)-positive and ALK-negative ALCL, which altogether represent about 15-20% of noncutaneous PTCLs, primary cutaneous ALCL (pcALCL) and the recently characterized provisional entity, breast implant-associated ALCL (BI-ALCL) [9] .
In ALK-positive ALCL, ALK expression results from the fusion of the ALK gene to various partners, most commonly NPM1 (nucleophosmin). It occurs mainly in children or young adults, may involve lymph nodes and/or various extranodal sites and has an overall excellent prognosis. Recently, an increasing number of cases of cutaneous ALCL positive for ALK expression have been reported both in children and adults, which presented as isolated cutaneous lesions without systemic involvement, and in most instances did not disseminate outside the skin and had an excellent outcome, arguing against the contention that ALK expression in ALCL is usually the indication of a systemic disease, and suggesting that ALK rearrangements represent that pathogenic event in a small subset of pcALCLs [49] .
ALK-negative ALCL tends to occur in older individuals and encompasses genetic heterogeneity, and two separate studies have now shown the clinical correlations to the genetic subgroups. Those with rearrangement of the DUSP22 locus @ 6p25 (about one third of the cases) have a good outcome similar to that of ALK-positive ALCLs; conversely, the small subset of ALK-negative ALCLs with TP53 rearrangements has a very poor outcome [50 & ]. pcALCL is an ALK-negative ALCL within the spectrum of primary cutaneous CD30 þ lymphoproliferative disorders (which also encompasses various types of lymphomatoid papulosis), and usually portends a good prognosis. Recent findings have shown partial overlap in the pathogenic mechanisms of primary cutaneous and systemic ALK-negative ALCLs. Nevertheless, the reasons underlying the distinctive clinical features of primary cutaneous versus systemic ALCL remain unknown. About one third of pcALCLs carry DUSP22 rearrangements [51] and some of these feature a biphasic pattern (dermal infiltrate of medium-to-large cells, and epidermotrophism by small atypical lymphocytes) similar to that seen in uncommon DUSP22-rearranged lymphomatoid papulosis [52] Two cases of pcALCL with TP53 rearrangements were reported with an aggressive clinical course but experience is limited to draw definitive conclusions. [53] Translocations involving the TYK2 tyrosine kinase have been found in a small subset of pcALCL and lymphomatoid papuloses, and also in systemic ALK-negative cases [54, 55] . The best characterized translocation encodes a NMP1-TYK2 fusion protein that induces TYK2 activation, STAT1/3/5 activation, but other gene partners in variant translocations are not known. Enhancer of zeste homolog 2 (EZH2), a catalytic unit with histone methyltransferase activity, is consistently overexpressed in pcALCL neoplastic cells, and showed how mechanistically epigenetic silencing by EZH2 deregulation might promote tumor progression, by inhibiting tumor cell apoptosis and by derepressing CXCL10 and increasing the influx of effector T cells to the lesions [56] .
BI-ALCL is a new provisional PTCL entity [9] with morphological and immunophenotypical features indistinguishable from those of other ALKnegative ALCL, and a specific clinical presentation, adjacent to a breast implant. Most cases confined to the periprosthetic effusion and capsule (seroma or ''in situ'' lymphoma) have excellent outcomes, and a minority of patients present with a breast tumor mass, which is an adverse prognostic factor [57, 58] .
A recent population-based case-control study from the Netherlands concluded to a very high (over 400) relative risk for BI-ALCL in women with breast implants, but to a small absolute cumulative risk with about one of 7000 women with breast implants would develop BI-ALCL before the age of 75 [59] . The pathogenesis of BI-ALCL remains elusive. It has been suggested that a local inflammatory response elicited by silicone-derived products or bacteria adherent to the surface of the prosthesis might play a role. Genetically, while cell lines derived from BI-ALCL effusions have unstable and complex karyotypes [60] , the few primary lymphoma samples examined so far show no or few alterations. The recurrent translocations found in other ALK-negative ALCL have not been found [57, 61] . Conversely, similar to other ALK-negative ALCLs, activation of STAT3 is common and mutations of JAK1 or STAT3 have been reported in individual case reports and small series [61, 62, 63, 64] .
LYMPHOMAS OF THE INNATE IMMUNE SYSTEM
Extranodal noncutaneous PTCLs derive from cytotoxic cells of the innate immune system. Apart from Pathogenesis of T-cell lymphomas Lemonnier et al.
EBV-associated extranodal NK/T-cell lymphoma (ENKTCL) which is not uncommon in Western countries and relatively frequent in Asia, hepatosplenic T-cell lymphoma (HSTL), enteropathy-associated T-cell lymphoma and monomorphic epitheliotropic T-cell lymphoma (MEITL) are rare or very rare diseases. Mutation-induced activation of the JAK-STAT pathway (usually mutually exclusive JAK1, JAK3, STAT3, STAT5B mutations) is a hallmark pathogenic mechanism common to these extranodal PTCLs. Interestingly, addiction to JAKs/STATs, irrespective of mutations, may be antagonized by pharmacological inhibitors [65] .
There is a wide spectrum of EBV positive NK/Tcell lymphoproliferations/lymphomas in adults and children, which are clinically heterogeneous (leukemic, extranodal lesions, nodal involvement and cutaneous) with more or less indolent or aggressive behavior (Table 1) . ENKTCL is an angiocentric and angiodestructive lymphoma of NK or less commonly T-cell derivation. In ENKTCL, mutations in JAK3, STAT3 and STAT5b often co-occur with epigenetic mutations (BCOR, others), and mutations in DDX3X which encodes an RNA helicase and in TP53 [66] . A genome-wide association study identified polymorphism in HLA-DP, rs9277378, as a risk factor for ENKTCL, reinforcing the role of HLA-DP presentation in oncogenesis [67] . Cases with upper aerodigestive presentation have a better outcome than those presenting elsewhere. Exclusively nodal presentation is uncommon and associated with a shorter survival, and interestingly gene expression and copy number alterations in nodal versus extranodal cases have been found different [68] . A subset of ENKTCL may develop a hemophagocytic syndrome, and a genetic basis -a specific mutation in ECSIT, an immune regulatory gene -was recently discovered for this often fatal hyperinflammatory complication. Functional studies nicely demonstrated that ECSIT-V140A variant activates nuclear factor-kappa B signaling and induces proinflammatory cytokine production, and the possibility of specific pharmacologic inhibition [69 & ]. Aggressive NK leukemia harbors a mutational pattern similar to ENKTCL, with mutations in DDX3X, STAT3 and in the RAS/MAPK pathway [70] .
HSTL and MEITL are rare, highly aggressive and essentially incurable diseases, most commonly derived from g-d T cells, the former involving the spleen and liver with a sinusoidal pattern in young individuals, the latter forming tumors derived from intestinal intraepithelial lymphocytes in individuals with no history of celiac disease or enteropathy [71] . Both entities frequently feature JAK/STAT pathway activation, most often due to STAT5B mutations Apart from T-cell lymphomas, mucosal lymphoproliferations of clonal T or NK cells with an indolent behavior were recently described in the digestive tract [74] . The gastrointestinal indolent T-cell lymphoproliferative disorder encompasses heterogeneous immunophe-
þ cases may progress to a malignant T-cell lymphoma [75] . Recently, STAT3-JAK2 fusions were discovered in four of five CD4 þ cases, whereas none of the other five cases with CD8 þ or CD4 þ CD8 þ phenotypes harbored the fusion, which might be targeted by JAK2 inhibitors [76 & ].
CONCLUSION
High-throughput sequencing analyses of most PTCL entitieshavesubstantiallyimprovedourunderstanding of PTCL pathogenesis, and oncogenic events have been identified in most PTCL entities. The current challenge is to mount efficient therapeutic strategies targeting these aberrations to improve patients' outcome. 6.
